EGFR and non-small cell lung carcinoma: Even if second-generation inhibitors display a broad-spectrum inhibitory activity toward a large panel of ErbB family kinases, including EGFRT970M mutants [155], the clinical utility for NSCLC patients with developed resistance after treatment with first-generation inhibitors is limited due to increased inhibitory activity toward EGFRwt and significant gastrointestinal and dermatological side effects [156,157].